Introduction
This is the Tenth World Report on assisted reproductive technology (ART) and the fifth prepared by the International Committee for Monitoring Assisted Reproductive Technologies (ICMART) since 2006 (IWGROAR, 2001; Adamson et al., 2006; ICMART, 2009; Nygren et al., 2011) . The aim of this report is to provide international information on availability, effectiveness and perinatal outcomes of ART treatment cycles for 2004 and to allow benchmarking of ART practice.
Materials and Methods
The data for ART treatment cycles in 2004 were collected from five regional ART registries compiled from national registry data in Europe, North America and Australia/New Zealand, from individual ART clinics in Latin America and the Middle East, and from national registries directly reporting to ICMART in Asia and Israel. Ethics approval (2011-7-12 ) for this report was granted from the University of New South Wales.
The ICMART data collection uses forms describing the organization of each country's register, the practice of ART and the results of IVF, ICSI and frozen embryo transfer (FET) and includes initiated cycles, aspirations, transfers, clinical pregnancies, deliveries and newborns. These variables are further classified according to the fertilization technique, woman's age, number of embryos transferred and gestational age at delivery. Other forms describe preimplantation genetic diagnosis (PGD), oocyte donation (OD), immediate complications for women and congenital anomalies detected during the perinatal period.
The 2002 ICMART-World Health Organization (WHO) glossary (Vayena et al., 2002) was used as a reference for terminology. This report covers ART-initiated treatment cycles between 1 January 2004 and the 31 December 2004 and is based on aggregated country data. Data were supplied to the Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden, where data validation were undertaken, a statistical plan was developed with the investigators, and a statistical report was prepared. The delay in reporting of data is a result of logistical difficulties regarding international data collection as well as implementation of ICMART's revised data collection and analysis processes.
Data are presented by country and region. Where data were incomplete the methods used previously for the 2003 report were employed . When the number of initiated cycles was unavailable in a national or regional register, an estimation of this number was made by using the average cancellation rate. For national registries with incomplete coverage, the number of initiated cycles per country was estimated by using the reported clinical pregnancy rate (PR), average miscarriage rate and multiple live birth rate in the countries that reported all of these variables. There was variability in the reporting of maternal complications, fetal reduction and maternal surrogacy; this limited the generalizability of these data. There was variability in the quality and reporting of perinatal outcomes, particularly congenital anomalies data, and these data are not reported. There are no data on causes of perinatal deaths.
Lastly, the estimated total number of babies born worldwide from ART procedures in 2004 was calculated using the hypothesis that the missing countries, mostly in Asia, Africa, Oceania and West Indies, performed between 10 and 20% of the world activity in ART. Availability is expressed as the number of cycles (estimated) per million inhabitants in 2004 (The World Factbook, 2005) . A cumulative delivery rate (DR) per aspiration was estimated by adding the FET deliveries to those obtained from fresh cycles and dividing the sum by the number of aspirations.
Results
The results are presented in Tables I -IV 
Availability
Data were received from 2184 clinics in 52 countries, representing 475 more clinics and 2 fewer countries than in 2003 . These clinics represented 79.3% of all registered clinics in those countries. Europe was the region with the largest number of clinics providing data to ICMART (n ¼ 785/1121; 70.0%) (Supplementary data, Table SI) . At a country level, Japan followed by the USA had the highest number of participating clinics at 620 (n ¼ 627, 98.9%) and 349 (n ¼ 463, 80.6%). Twenty-four countries could provide data on .95% of cycles that were performed in their country. The number of cycles completed per year by reporting clinics varied markedly by geographic location. Clinics reporting ,100 cycles were mainly located in Asia (61.6%) and Latin America (42.2%) and large-volume clinics (.1000 cycles, 100% participating clinics) were located in Slovenia (66.7%), The Netherlands (61.5%), Belgium (44.4%), Australia (36.0%), Israel (29.2%) and New Zealand (25.0%). Denmark  9598  9214  5299  3915  NA  1565  1384  NA  58  11 221  2073  Finland  4761  4647  2849  1798  NA  3434  3037  NA  820  9015  1729   France  55 217  50 192  21 749  28 443  NA  13 648  12 072  196  231  69 292  1147   Germany  NA  38 824  12 211  26 613  NA  19 269  17 043  NA  NA  61 413  745  Greece  7577  7851  2662  5189  NA  1222  1081  96  269  NA  NA   Hungary  2593  2498  639  1859  NA  280  248  1  28  5320  530   Iceland  NA  234  107  127  NA  83  73  0  8  345  1174  Ireland  2114  1837  1079  758  NA  459  406  NA  0  3002  756   Italy  23 711  20 968  6233  14 735  NA  2488  2201  NA  NA  42 943  740   Latvia  138  134  85  49  NA  50  44  0  2  570  247  Lithuania  NA  83  45  38  NA  8  7  0  0  294  81   Macedonia  521  489  283  206  NA  1  1  0  NA  NA  NA   Netherlands  15 297  13 959  8273  5686  NA  2287  2023  69  NA  17 653  1082  Norway  5136  4952  2692  2260  NA  937  829  0  NA  6073  1328   Poland  3675  3592  550  3042  NA  1317  1165  0  100  7638  198   Portugal  NA  2491  848  1643  NA  374  331  NA  21  3464  329  Russia  12 052  11 656  8281  3375  NA  1768  1564  87  910  16 299  113   Serbia  181  160  11  149  NA  NA  NA  NA  2  732  68   Slovenia  2100  2016  656  1360  NA  601  532  5  17  2723  1354  Spain  27 481  24 315  4537  19 778  NA  5059  4475  1362  4219  82 In countries in which the sum of singleton, twins and triplets were less than the total number of deliveries, the numbers of unknown babies and lost-to-follow-up deliveries were estimated by applying the distribution of reported deliveries in these countries. In countries in which the sum of singleton, twins and triplets was less than the total number of deliveries, the numbers of unknown babies and lost-to-follow-up deliveries were estimated by applying the distribution of reported deliveries in these countries. (Table II) Overall, the proportion of women aged ≥40 years having ART treatment cycles was 14.9% compared with 14.6% in 2003. The proportion of older women accessing ART varied among countries and regions, with Italy, Greece, Australia and Serbia having more than one in five cycles to women aged ≥40 years (Supplementary data, Table SIII) .
Safety and quality
The proportion of single embryo transfers (SETs) increased from 14.7% in 2003 to 16.3%, with the highest levels reported by Sweden (67.4%), Belgium (48.9%) and then Finland (47.0%) ( Table III) . The proportion of twin deliveries marginally increased from 24.8% in 2003 to 25.1%, while the proportion of triplet deliveries continued to decrease, from 2.0% to 1.8%. However, these rates differed largely among countries; the percentage of twin births ranged from 5.6% in Sweden to 48.2% in Peru, and births of triplet and higher order multiples from ,1% in several countries (including Sweden, Belgium, Australia, New Zealand, Norway, Denmark and France) to .10% in Lithuania and six Latin American countries (Argentina, Brazil, Ecuador, Guatemala, Mexico and Venezuela) (Supplementary data, Fig. S1 ). Similar rates of multiple deliveries were seen for FET in 2003 and 2004 , with twins at 17.0% and triplets or higher at 1.0% (Supplementary data, Table SII ). The percentage of transfers with four or more embryos in fresh cycles increased slightly, to 11.6% from 10.8% in 2003, but with major differences among and within regions (Table III) . The lowest proportion of ≥4 fresh embryo transfers was reported from Australia/New Zealand at 0.4% then Europe at 3.3% and the highest from Asia at 42.5% with the Nordic countries reporting no embryo transfer cycles of ≥4. The mean number of embryos transferred was lowest from Australia and New Zealand, 1.67 and 1.76, respectively (Table III) . Figure 3 shows the DR per aspiration varied by both individual country and mean number of embryos transferred. The mean number of embryos (Table IV) . These data must be interpreted with caution as no data from European countries were available on these birth outcomes and this may bias the results. The frequency of ovarian hyperstimulation syndrome (OHSS) was reported as 1.2%, with a regional range of 0.2-7.5% (Supplementary data, Table SIV ). Three countries (Taiwan, Portugal and Slovenia) reported .10% of cycles resulted in OHSS.
Special techniques-ovum donation, PGD, in vitro maturation, surrogacy and multifetal reduction Table SV) . Of these transfers, 44.4% were performed in the USA and 72.2% were fresh embryos transfers. DRs per transfer (fresh plus FET) was 34.1%, with the USA highest at 44.7%. The multiple DR from OD transfers was 34.6%. Of the 12 334 babies reported from OD, 60% were born in the USA. Eighteen countries reported 2739 PGD aspiration cycles, with PR and DR per aspiration at 21.9 and 15.9%, respectively (Supplementary data, Table SVI ). Very few data were reported on in vitro maturation, surrogacy and multifetal reduction. Monitoring of ART practice, effectiveness and outcomes at an international level is central to improving fertility services and outcomes worldwide and to monitoring the impact of policy initiatives, such as SET, over time. It is important to monitor ART to determine availability and access to fertility services, the benefits and risks of new technology and the changes in practice as well as to benchmark treatment and perinatal outcomes. The latter is critical to developing comprehensive statistics to inform policy and planning of ART-related health care and to provide an evidence base on ART for populations seeking fertility treatment.
Availability
One way of measuring access to ART is the number of countries that provides ART services. In 2004, there remained enormous variability A second crude population measure of availability is the number of ART cycles per million population. This measure is inherently unstable, affected by a country's government policy, regulation, funding and the number of service providers, and has continued to fluctuate with each ICMART report. Interpretation of this measure needs to be contextualized to the local legislative frameworks that countries operate under for the practice of ART. Notably, there is enormous variability internationally with the majority of countries having either mandatory governmental regulations or voluntary guidelines promulgated by professional societies, the latter often having significant involvement in the regulation and licensing of ART clinics. In contrast, in 2004 Canada, Finland and a number of countries from South America did not have guidelines or regulations in place (IFFS, 2004) . In 2004, availability ranged from ,100 cycles per million population in several Latin American countries to a pro-natalist high of 3844 cycles per million population in Israel: the latter reflects both the policy framework and the availability of public or third-party payment for ART cycles. In 2004, Israel had a policy of full financial coverage for ART (for 2 children), while Australia (1854 cycles per million population) had a mixed model of partial public sector, private health insurance coverage with a varying amount of patient's out of pocket payments. In contrast, the USA and Canada had partial coverage from private health insurance (498 per million) and no coverage (334 per million) and this is reflected in their level of availability (IFFS, 2004) . These proxy measures do not replace the need for better information on the proportion of women/couples with infertility accessing ART treatment, as well as an internationally accepted measure of cost and affordability of ART treatment.
Practice change
The trend of an increasing proportion of ICSI continued in 2004 with 60.6% of all cycles being ICSI compared with 56.6% in 2002 and 47.6% in 2000. This trend in the increase of ICSI versus conventional fertilization was seen across all regions. Notably, four countries (Saudi Arabia, Jordan, Turkey and Egypt) reported that 98% or more fresh nondonor aspirations were ICSI. In contrast, only three countries (Russia, Ukraine and Guatemala) reported ,30% of fresh non-donor aspirations were ICSI. At a regional level the use of ICSI varied from 60% in Europe to 76% in Latin America. This provides confirmation of the adoption of ICSI as the preferred fertilization practice for ART internationally. This practice change is evidence based for male factor and for combined male/female factor infertility but may require further justification for other causes of infertility (Nangia et al., 2011; Halliday, 2012) . There is a lack of international agreement of the overall benefit of using ICSI where conventional fertilization traditionally would have been the first-line management.
A number of studies report differential perinatal risks associated with the use of either IVF or ICSI (Bonduelle et al., 2002 , Lie et al., 2005 Al-Fifi et al., 2009; Davies et al., 2012) while others have found no marked difference (Källén et al., 2005 (Källén et al., , 2010 Romundstad et al., 2008) . The development of additional data items on the indication for ICSI or IVF and origin of sperm would be a first step in monitoring this change in practice and allow evaluation of its impact on pregnancy and perinatal outcomes. Additionally, gamete intraFallopian transfer (GIFT) is no longer usual practice and is no longer available or monitored in the majority of countries and its exclusion from future world reports should be considered. .1% and 13.7 to 11.6%, respectively, and this has contributed to the decline in the trend of multiple deliveries following ART. However, this practice was not uniform with only the Australia and New Zealand region reporting an overall proportion of ,5% for embryo transfers ≥3. Twelve countries, primarily from Europe, reported no embryo transfers ≥4 in contrast to 15 countries who reported 20% or more embryo transfers ≥4, peaking at 54%. Taiwan had three quarters of its embryo transfers ≥3 and reported 35.6% of deliveries were preterm with a perinatal mortality of 45.0 per 1000 births for fresh non-donor cycles. In contrast, New Zealand had only 3.8% embryo transfers ≥3 and reported fewer adverse perinatal outcomes with 18.9% of deliveries preterm and a perinatal mortality of 8.1 per 1000 births for fresh non-donor cycles. Comparatively, three countries (Sweden, Finland and Norway) reported ,1% of triple embryo transfers versus 30 countries who reported 20% or more of triple embryo transfers. The variability in practice demonstrated by these findings continues to provide stark evidence that the most modifiable, preventable risk factor to prevent multiple pregnancy and its known sequelae is the number of embryos transferred per procedure.
Safety and quality
The European Perinatal Health Report used data from 2004 for all births from 25 European countries belonging to the European Union in addition to Norway (EURO-PERISTAT, 2008) . In these European countries, the multiple birth rate (per 1000 women giving birth) for twins ranged from 11 to 23 and for triplets from 0.1 to 1.6 (EURO-PERISTAT, 2008). Comparatively, for women giving birth following ART, the estimated multiple birth rate (per 1000 women giving birth after ART) for twins ranged from 178 in the Australia and New Zealand region, to 217 for Europe, to 374 for Latin America and for triplets from 4 in the Australia and New Zealand region, to 10 in Europe and to 13 for Latin America. Notably, the proportion of higher order multiples has markedly declined since 1998 but major differences persist among regions with only selected Nordic countries and Australia and New Zealand approaching spontaneous conception population rates of higher order multiples of ,1 per 1000 women giving birth (IWGROAR, 2001; Adamson et al., 2006; ICMART, 2009; Nygren et al., 2011) .
Effectiveness
Most change in practice was to SET with the mean percentage increasing by almost four percentage points to 16.3%. This reflects the change in practice to SET for a number of countries, predominantly from Europe. Three European countries reported SET in over 45% of cycles: Sweden 67.4% (increased from 30.6% in 2002), Belgium 48.9% (increased from 16.5% in 2002) and Finland 47.0% (increased from 38.7% in 2002). In parallel, the overall proportion of FET cycles increased to 31%. This seven percentage point increase in FET cycles would have likely impacted the cumulative PR with an overall lower pregnancy (24.1) and DR (16.6) than for fresh transfer cycles. Interestingly, the DR for fresh IVF and ICSI combined fell three percentage points to 20.4%, while the cumulative DR (fresh plus frozen cycles) decreased two percentage points to 24.3%.
Effectiveness remains difficult to measure using cycle rather than women-based data because cumulative PRs cannot be calculated directly but can only be indirectly estimated. The measure of effectiveness is further limited by the incomplete data on access and outcomes of ART, and standard populations to compare ART with spontaneously conceived infants. At an international level, this type of detail is not feasible or warranted. Instead, record linkage at a country level with perinatal registers has been used successfully to measure effectiveness and to demonstrate improving neonatal outcomes for ART babies when compared with spontaneously conceived babies (Romundstad et al., 2008; Källén et al., 2010) . Higher incidences of congenital anomalies and of both autosomal and sexchromosome abnormalities specifically have been reported in both IVF and ICSI compared with spontaneously conceived infants (Bonduelle et al., 2002; Al-Fifi et al. 2009; Finnströ m et al., 2011; Davies et al., 2012) . The variable quality and limited international data for congenital anomalies limits monitoring of the short-and medium-term outcomes of babies and evaluation of the risks of new technology and changes in practice.
Limitations
The quality and completeness of data reflect local data collection practice. This varies by individual country and region and is dependent upon the local regulatory environment and whether data supply to the national or regional registries is voluntary or mandatory. Although many countries submitted incomplete data, the major outcomes (procedures, pregnancies, deliveries and babies) are largely comparable across registries. The promotion of data standards and common terminology internationally has strengthened since 2002 with the development of the original and then revised ICMART glossaries (Vayena et al., 2002; Zegers-Hochschild et al., 2006a,b; Zegers-Hochschild et al., 2009a,b) ; and more recently with the publication of the ICMART toolkit which is designed to support data collection practice for countries setting up registries to monitor ART. However, there may still be discrepancies in the use of the ICMART glossary and the data available in countries and these data need to be interpreted with caution.
In 2004, one-fifth of the clinics in participating countries did not report information on ART treatment and outcomes to their national and/or regional registries. This may reflect the local regulatory environment for ART practice including requirements for national reporting. Critically, factors such as whether the collection is mandatory or voluntary, has leadership and support from the country's leading professional fertility organization, and its funding model, e.g. government, patient or private sector funded, underpin the sustainability of the collection and quality of monitoring at the country level. The value of the world report is its capacity to benchmark practice internationally; the limitation is that this benchmarking is only as valid as the data supplied. The most significant gaps in the data remain a number of populous countries, including China, Pakistan, Bangladesh, Indonesia, Philippines and regional sub-Saharan Africa, which do not have registries.
Conclusion
In conclusion, this world report has shown a continued increase in the number of reporting clinics and ART treatment cycles worldwide. However, there remains significant variability in ART practice and outcomes. Of note is the continuing rise in ICSI worldwide and the slow but steady adoption SET as the first-line management for selected women/couples. These changes in practice are already differentially impacting the multiple birth rate and perinatal outcomes of countries, with Australia and New Zealand, Europe and North America continuing to reduce the proportion of multiple births, particularly higher order multiple births, in contrast to increases in Asia and the Middle East. 
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